Immune tissue chemical diagnostic kit used for pathological diagnosis of tumour

An immunohistochemistry and diagnostic kit technology, applied in the field of bioengineering, which can solve the problems of poor repeatability, unsatisfactory results, and large differences between antibody batches

Active Publication Date: 2009-12-09

FOURTH MILITARY MEDICAL UNIVERSITY

1 Cites 31 Cited by

AI-Extracted Technical Summary

Problems solved by technology

There is no formal batch number, and the antibodies used in pathological diagnosis have la...

Method used

Conclusion: use the immunohistochemical diagnostic kit of the HAb18G/CD147 cancer marker for tumor pathological diagnosis of the present invention, carry out immunohistochemical staining and can obtain good staining result, and its cell membrane positive staining is clear, clear, almost nothing more than Specific staining can obtain accurate judgment results.

The immunohistochemical diagnostic kit of the HAb18G/CD147 cancer marker used for tumor pathological diagnosis of the present invention adopts the basic principle of the specific combination of immunological antigen and antibody "one-to-one", and uses specific HAb18 antibody Stain the tissue, and further clarify the relationship between the HAb1...

Abstract

The invention discloses an immune tissue chemical diagnostic kit of HAb18G/CD147 cancer landmark used for pathological diagnosis of tumour, including a blocking agent capable of removing endogenous enzyme in a human tissue slice, a sealing agent used for sealing cross protein reaction in the human tissue slice, a first antibody capable of combining with the HAb18G/CD147 cancer landmark in human tumour tissue, a biotin marked secondary antibody capable of combining with the first antibody, and an enzyme marked avidin, chromogenic reagent and a phosphate buffer system used for combining with the secondary antibody. The kit has the characteristics of good specificity, high sensibility, stability and universality, is mainly used for pathologic diagnosis of epithelium-derived malignant tumour (such as liver cancer, lung cancer, esophageal cancer, gastric cancer, colorectal cancer, breast cancer, cervical cancer, ovarian cancer and the like), and is beneficial to warning screen, early diagnosis, etiologic diagnosis, treatment reaction and curative effect monitoring of tumour, recrudescence and transfer and prognosis judgement of tumour.

Application Domain

Preparing sample for investigation

Technology Topic

Premalignant NeoplasmAntibody +21

Image

Examples

Experimental program(4)

Example Embodiment

[0046] The following are specific examples given by the inventor:

[0047] The experimental method of the HAb18G/CD147 cancer marker immunohistochemical diagnosis kit is as follows. The following examples refer to this method, referred to as "experimental method":

[0048] 1. Paraffin sections of clinical tissue cases, deparaffinized with xylene for 20 minutes, 3 times;

[0049] 2. 100% alcohol to remove xylene, 5min, 2 times; 95%-75% alcohol, 2min/time;

[0050] 3. 3% H2O2 blocked endogenous peroxidase, 22-28℃, 10 minutes;

[0051] 4. Soak in PBS buffer for 3 minutes, 3 times;

[0052] 5. 5% normal goat serum to block non-specific sites in the tissue, 22-28°C, 20 minutes;

[0053] 6. HAb18 monoclonal antibody (30ug/mL), 37°C, 120 minutes;

[0054] 7. Soak in PBS buffer for 5 minutes, 3 times;

[0055] 8. Avidin-labeled anti-specific anti-antibody, 22-28°C, 15 minutes;

[0056] 9. Soak in PBS buffer for 5 minutes, 3 times;

[0057] 10. Horseradish peroxidase labeled biotin, 22-28℃, 20 minutes;

[0058] 11. Soak in PBS buffer for 5 minutes, 3 times;

[0059] 12. DAB color development, 22-28℃, 2-10 minutes;

[0060] 13. Hematoxylin lining the nucleus, 22-28℃, 5 minutes;

[0061] 14. 5%-95% alcohol, 2min/time; 100% alcohol dehydration, 5min, 2 times;

[0062] 15. Xylene is transparent, 5min, 2 times; observation under microscope.

[0063] Selection of the research object: The gold standard HE staining method is used as the basic condition for determining the samples of the case group and the control group, and the selection of the research object is determined according to histopathological morphological characteristics.

Example Embodiment

[0064] Example 1:

[0065] The specific test process for the expression of HAb18G/CD147 cancer marker immunohistochemical diagnosis kit for the auxiliary diagnosis or differential diagnosis of cancer in liver tissue is as follows:

[0066] 1. Sample selection: (For liver cancer, determine the case according to the gold standard HE staining)

[0067] Table 1 Selection of cases of liver cancer and liver tissue

[0068]

[0069] 2. Test operation: see "Experimental Method" for details.

[0070] 3. Test results: (see attached figure 2 A)

[0071] Table 2 Staining results of HAb18G/CD147 cancer marker diagnostic kit in liver cancer and liver tissue

[0072]

Example Embodiment

[0073] Example 2:

[0074] The specific test process for the expression of HAb18G/CD147 cancer marker immunohistochemical diagnosis kit for the auxiliary diagnosis or differential diagnosis of cancer in lung tissue is as follows:

[0075] 1. Sample selection: lung cancer, according to the gold standard HE staining method to determine the case

[0076] Table 3: Case selection of lung cancer and lung tissue

[0077]

[0078] 2. Test operation: see "Experimental Method" for details.

[0079] 3. Test results: (see attached figure 2 B)

[0080] Table 4: Staining results of HAb18G/CD147 cancer marker diagnostic kit in lung cancer and lung tissues

[0081]

PUM

Description & Claims & Application Information

We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.